Status:
COMPLETED
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Lead Sponsor:
Chao Ji
Conditions:
Immune Checkpoint Inhibitor-Induced Dermatitis
Stevens-Johnson Syndrome, Drug-Induced
Eligibility:
All Genders
Brief Summary
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment. With the increasing use of immune checkpoint inhibitors (IC...
Detailed Description
Introduction: Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction characterized by extensive skin detachment. With the increasing use of immune checkpoint ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of SJS/TEN induced by any drugs
- Have the immune-related cutaneous adverse events
Exclusion
- Incomplete medical records
- Unknown the specific culprit drugs
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06522048
Start Date
January 1 2015
End Date
May 1 2024
Last Update
July 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350000